Moderna Share Price: Q1 2021 Results Preview
Shaun Murison | May 05, 2021 15:33
When is Moderna’s earnings date?
The Moderna (NASDAQ:MRNA) earnings release date is scheduled for 6 May 2021. The results will cover the group's quarter one (Q1) financial year 2021 (FY21) earnings (January to March 2021).
Moderna results preview: what does the Street expect?
Moderna has said that 2021 will be a pivotal year for the group's future success as years of research now move to profitability with commercial operations now well underway. The company’s improved cash flow is now allowing for increased scalability, evident in recent news that the Massachusetts manufacturing facility will see its 300,000 square foot operations expanded to more than double its current floor space.
Project priorities indicated by the group in 2021 include:
- 1. Maximising the impact of Moderna Covid-19 vaccine access and the value creation of this product between now and the end of 2021
- 2. Accelerate vaccine development to advance their pipeline and bring new vaccines to market
- 3. Generate human proof-of-concept data in autoimmune diseases, cardiovascular diseases, oncology and rare diseases
- 4. Continue to expand the use of mRNA technology to maximize the potential impact they can have on patients
Investors will look to Moderna’s progress regarding the aforementioned goals. In terms of the upcoming results, ‘the Street’ arrives at the following consensus estimates:
- Revenue for the quarter expected at $2.04 billion
- Earnings per share (EPS) for the quarter expected at $2.39
How to trade Moderna Q1 results
The two graphics below provide traders with both a retail short-term view on the stock, as well as an institutional longer-term view on the Moderna share price, as to how market participants are positioned ahead of the Q1 earnings release.
Source: IG
A Refinitiv poll of 16 analysts maintain a long-term average rating of ‘hold’ for Moderna (as of 4 May 2021), with two of these analysts recommending a strong buy, six recommending a buy, five hold, three sell and zero strong sell recommendations on the stock. The long-term price target mean from these analysts of $175.50, suggests the current share price to be trading at a 3% premium to the suggested fair value.
Source: IG
Get The App
From a retail trader perspective (as of 3 May 2021), 86% of IG clients with open positions on the Moderna expect the share price to rise over the near term, while 14% of IG clients with open positions expect the Moderna price to fall.
Moderna share price: technical analysis
Source: IG charts
The Moderna share price currently trades in a broad range over the medium term between levels $117.10 (support) and $189.25 (resistance). In the short term, we are seeing a bearish price reversal forming at resistance of this range. The bearish reversal is supported by an overbought signal on the stochastic oscillator. The bearish reversal at resistance whilst in overbought territory suggests short-term weakness with $156.95 the initial support target. Traders who are short might consider using a close above the $189.25 level as a stop loss indication for the trade.
Original Post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.